Modern treatments are hugely expensive to develop, and they also tend to be very specific (ie. only 1 in 5,000 people might get the exact right kind of brain tumour for your treatment to be an option).
With only about 1 million all-cause deaths per year in the UK, that means your treatment for a specific terminal brain tumour might only have 200 patients per year.
The 'we just saved 4 hours of clinician time by using fancy AI' just isn't worth it if it only saves 800 hours of clinician time per year, yet costs millions to develop.
The fix is to roll this out somewhere with more patients (eg. China) and where trials are cheaper (ie. China).
Use rugged AI like coolwulf. That's what's up. He hauled ass, be like coolwulf.
No don't be like coolwulf, be coolwulf. Be him, do what he did, make the algorithms from your brain protect the algorithms that make up your brain. You know they're symbiotic right?
Transistor and neuron fighting together against destruction. Symbiosis.
EDIT: coolwulf might as well be John von Neumann, the last line of defense against brain cancer and brain surgery, those neurons reaching beyond the skull to make a change in the World for some part of that World to then reach inside that skull and protect it. The chip as the final garrison of the biological human brain. Ghost in the Shell. Ghost retreating from the Shell and regrouping, no ruling out whether it can triumph when it returns to reconquer its damaged Shell.
Modern treatments are hugely expensive to develop, and they also tend to be very specific (ie. only 1 in 5,000 people might get the exact right kind of brain tumour for your treatment to be an option).
With only about 1 million all-cause deaths per year in the UK, that means your treatment for a specific terminal brain tumour might only have 200 patients per year.
The 'we just saved 4 hours of clinician time by using fancy AI' just isn't worth it if it only saves 800 hours of clinician time per year, yet costs millions to develop.
The fix is to roll this out somewhere with more patients (eg. China) and where trials are cheaper (ie. China).